DIRECT, led by Co-Principal Investigators – Govindarajan Narayanan, MD, Chief of Interventional Oncology at Miami Cancer Institute and Robert C.G. Martin, MD, PhD, Surgical Oncology at the University of Louisville, is looking to better patient care by uncovering potentially new treatment options for those suffering with locally advanced pancreatic cancer.
DIRECT is a clinical study composed of two protocols that will evaluate the efficacy and safety of using Irreversible Electroporation (IRE) technology to ablate malignant pancreatic tumors in people diagnosed with stage III pancreatic cancer. The trial is set up to evaluate both real-world results from the Registry, and additional results from the Randomized Control Trial. The unique trial design is made possible by the use of Electronic Medical Record (EMR) technology to directly capture study data, thus, reducing the burden on patients and clinicians.
The clinical study is currently enrolling patients. If you are a physician or clinical staff member that has a potentially qualifying patient or would like to learn more about getting involved with the study, please call our support line at +1 (800) 584-7608 or email us at firstname.lastname@example.org.